Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities. Get Free Email Updates

Stay Competitive With Stock Market Updates!

Get Free Updates


Atossa Therapeutics, Inc.

  ( )

vista's key points

  • Atossa is led by Dr. Stephen Quay, MD, PhD. who has invented 7 FDA-approved pharmaceuticals which have helped over 80 million people
  • Atossa's COVID-19 HOPE Treatment Program uses AT-H201 for severely ill patients to improve lung function and reduce the amount of time that COVID-19 patients are on ventilators
  • Atossa's AT-301 Nasal Spray therapy for at-home use immediately following diagnosis of COVID-19 to proactively reduce symptoms of COVID-19 and to slow the infection rate so that a person’s immune system can more effectively fight the virus
  • Atossa is developing their proprietary Topical & Oral Endoxifen to both help prevent as well as to treat breast cancer
  • Atossa recently raised $62.2M in gross proceeds to bolster its balance sheet, extend runway, & increase corporate options.

company profile


vista's view

Atossa's current valuation is ~$50M and with a balance sheet that was recently strengthened with 3 equity raises that brought in $62.2M in gross proceeds. With the additional funds their funded development runway has been extended significantly which we believe make's it an interesting 'value' play in the biotech sector....

Read More

Page View Count : 532680

exclusive content


Vista Partners creates exclusive content based on the ongoing research of companies included in the VP Watchlist.

vp watchlist

The VP Watchlist contains current coverage companies that deserve consideration for short term and long term portfolio additions.